Clinical Trials Logo

Esophagitis clinical trials

View clinical trials related to Esophagitis.

Filter by:

NCT ID: NCT03214952 Completed - Clinical trials for Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis

Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"

Start date: March 1, 2016
Phase:
Study type: Observational

The purpose of this survey is to evaluate the safety and effectiveness of vonoprazan tablets in patients with gastric ulcer, duodenal ulcer, and reflux esophagitis in the routine clinical setting.

NCT ID: NCT03214081 Completed - Reflux Esophagitis Clinical Trials

Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"

Start date: March 1, 2016
Phase:
Study type: Observational

The purpose of this survey is to evaluate the safety and effectiveness of long-term administration of vonoprazan tablets when used as maintenance therapy for reflux esophagitis in routine clinical settings.

NCT ID: NCT03191864 Completed - Clinical trials for Eosinophilic Esophagitis

Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)

FLUTE
Start date: June 22, 2017
Phase: Phase 2
Study type: Interventional

Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus, characterized by eosinophilic infiltration and gastrointestinal symptoms. Swallowed, topically acting corticosteroids, such as fluticasone, appear to be effective in resolving acute clinical and pathological features of EoE. APT-1011 is an orally disintegrating tablet (ODT) formulation of fluticasone propionate. This study is designed to compare the efficacy and safety of APT-1011 with placebo in adults with EoE for an initial 12-week treatment period, followed by an additional 40-week maintenance treatment phase. Histologic response, pharmacokinetics, and dysphagia will be assessed.

NCT ID: NCT03116841 Completed - Reflux Esophagitis Clinical Trials

Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation

VISTAEXE
Start date: August 2, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to exploratorily evaluate the effect of vonoprazan 20 mg on sleep disturbance of patients with reflux esophagitis, who have heartburn and/or regurgitation and ≥ 6.0 in the Pittsburgh Sleep Quality Index (PSQI) global score despite the maintenance treatment with PPI other than vonoprazan.

NCT ID: NCT03107819 Completed - Clinical trials for Eosinophilic Esophagitis

Metabolomics for Biomarker Discovery in Children With EoE

Start date: March 29, 2017
Phase:
Study type: Observational

The investigators are seeking to enroll 8 children ages 2-18 already undergoing upper endoscopy. For the purposes of research, a peripheral blood and clean catch urine specimen will be obtained to measure plasma and urine metabolomics. The data will be used to determine if there are any key differences in the metabolite profile of subjects found to have eosinophilic esophagitis (EoE) versus non-EoE subjects. Once these metabolites are identified, the investigators will seek to enroll many more subjects for a validation phase.

NCT ID: NCT03078023 Completed - Clinical trials for Eosinophilic Esophagitis

Sponge and Eosinophil Peroxidase (EPO) Staining

Start date: March 8, 2017
Phase: N/A
Study type: Interventional

Are we able to use the EPO staining technique using the sponge ?

NCT ID: NCT03069573 Completed - Clinical trials for Gastroesophageal Reflux

Phenotypic Characterization and Biomarkers Investigation for Eosinophilic Esophagitis in Pediatric Patients

Start date: January 1, 2015
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to find out some potential biomarkers for the Eosinophilic Esophagitis (EoE) in pediatric patients through the prospective clinical characterization and assessment of samples collected during the diagnostic process

NCT ID: NCT03068572 Recruiting - Clinical trials for Gastroesophageal Reflux Disease

Diagnostic Value of Linked Color Imaging for Minimal Change Esophagitis in Nonerosive Reflux Esophagitis and GERD

Start date: January 15, 2017
Phase: N/A
Study type: Observational

Linked color imaging(LCI),a new system for endoscopy modality,creates clear and bright endoscopic images by using short-wavelength narrow-band laser light combined with white laser light on the basis of magnifying blue laser imaging(BLI) technology.LCI makes red areas appear redder and white areas appear whiter.Thus,it is easier to recognize a slight difference in color of the mucosa.This is a study to assess the effectiveness of LCI for diagnosing esophageal minimal endoscopic lesions and Los Angeles classification system when compared to conventional white-light endoscopy (WLI).Gastroesophageal reflux disease(GERD) is a common disease that be defined as a condition which develops when the reflux of stomach contents cause troublesome symptoms and/or complications.Esophageal injury was classified according to the Los Angeles classification system,Non-erosive reflux disease(NERD) is defined by the presence of troublesome reflux-associated symptoms and the absence of mucosal breaks at endoscopy,which includes minimal change oesophagitis and no endoscopic abnormalities.LCI improved the visualization of the squamocolumnar junction (SCJ) by enhancing the contrast,mucosa minimal changes could be seen more easily and clearly with LCI than with standard white-light endoscopy.By comparing White-light endoscopy and LCI,it will show if there is any comparable advantage to using one or the other for lesion detection.

NCT ID: NCT03029091 Completed - Clinical trials for Eosinophilic Esophagitis

An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)

Start date: May 23, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the safety and effectiveness of Losartan potassium in subjects with eosinophilic esophagitis (EoE) including those with a connective tissue disorder (CTD) and those without a CTD.

NCT ID: NCT03006874 Completed - Erosive Esophagitis Clinical Trials

Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

Start date: May 2, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to confirm the efficacy of CJ-12420, Once daily (QD), compared to esomeprazole in patients with erosive esophagitis classified as Los Angeles (LA) classification grades A to D at Week 8.